New data on the inhalable insulin product Technosphere Insulin Afrezza, from MannKind Corp., indicate that the treatment confers no discernible risk for increased cardiovascular (CV) events, while another study examined patient satisfaction with this type of drug.…

Liraglutide, recently approved in the US for the treatment of type 2 diabetes, has demonstrated its potential as a weight-loss drug for nondiabetic, obese patients.…

Zinc may perform a protective function for those with type 2 diabetes, researchers at the University of Michigan suggest….

Users of the smoking-cessation drug varenicline (Chantix) had a small but statistically significant increase in the risk of cardiovascular events, a meta-analysis of randomized trials showed.…

Impaired fasting glucose doesn’t independently increase the risk of cardiovascular events in adults, according to a large new study.…

Patients with depression or diabetes have an increased risk of MI, but the risk is even higher in patients with both conditions, according to a new study.…

Menu labels on college cafeteria food — highlighting the good and the bad of various meal options — make no difference in students’ choices, a new study concludes.…

Discovery makes white fat mimic energy-burning brown fat, muscle.…

There was a news release that caught my attention this past week. Eli Lilly announced that the Exenatide tQT Study Showed No Prolongation of QT Interval (See this week’s Item #1). Back in March most of us thought that the FDA would approve the once weekly dose, but instead they …

Glucagon-like peptide-1 mimetics improve certain cardiovascular risk factors, although it is unclear if the observed benefits are direct effects or indirect effects due to weight loss. Improvements in systolic blood pressure seen in exenatide and liraglutide trials are illustrated in Figure 3. The decreases in systolic blood pressure range from …